Acadian Asset Management LLC Buys Shares of 157,266 REGENXBIO Inc. $RGNX

Key Points

• Acadian Asset Management LLC has invested approximately $1.12 million in REGENXBIO Inc., acquiring 157,266 shares during the first quarter, which represents about 0.31% of the company.
• REGENXBIO's stock has experienced volatility, trading up 3.7% recently, while analysts have mixed reviews—ranging from a "strong sell" to a "buy" rating with target prices between $17.00 and $52.00.
• The company reported a loss of $1.38 EPS for the last quarter, significantly missing consensus estimates, with overall revenue coming in at $21.36 million compared to expected $40.87 million.

Acadian Asset Management LLC acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 157,266 shares of the biotechnology company's stock, valued at approximately $1,123,000. Acadian Asset Management LLC owned about 0.31% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC acquired a new position in shares of REGENXBIO during the 1st quarter valued at about $484,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of REGENXBIO during the 1st quarter valued at about $123,000. BNP Paribas Financial Markets increased its holdings in shares of REGENXBIO by 370.1% during the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after acquiring an additional 75,652 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of REGENXBIO by 325.3% during the 4th quarter. Jane Street Group LLC now owns 164,911 shares of the biotechnology company's stock valued at $1,275,000 after acquiring an additional 126,135 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of REGENXBIO by 4.7% during the 4th quarter. Ameriprise Financial Inc. now owns 284,521 shares of the biotechnology company's stock valued at $2,199,000 after acquiring an additional 12,883 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Price Performance

Shares of RGNX traded down $0.47 during mid-day trading on Friday, reaching $8.89. The company had a trading volume of 744,358 shares, compared to its average volume of 482,013. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $12.47. The company's 50-day moving average is $8.78 and its 200-day moving average is $8.35. The company has a market capitalization of $449.03 million, a P/E ratio of -2.58 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The company had revenue of $21.36 million during the quarter, compared to analyst estimates of $40.87 million. As a group, equities analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Insider Transactions at REGENXBIO

In other REGENXBIO news, CEO Curran Simpson sold 7,734 shares of REGENXBIO stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $10.02, for a total value of $77,494.68. Following the completion of the transaction, the chief executive officer owned 244,597 shares in the company, valued at approximately $2,450,861.94. The trade was a 3.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 12.79% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on RGNX shares. Royal Bank Of Canada decreased their target price on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Barclays reduced their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.